Belzutifan plus cabozantinib shows promising antitumor activity in patients with clear-cell renal cell carcinoma not previously treated - research led by @danafarber.bsky.social’s @drchoueiri.bsky.social and published in The Lancet Oncology. https://bit.ly/4jciWIR
Comments